A review of vaccine research and development: Human acute respiratory infections

被引:137
作者
Girard, MP
Cherian, T
Pervikov, Y
Kieny, MP
机构
[1] Univ Paris 07, UFR Biochem, FR-69008 Lyon, France
[2] WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland
关键词
vaccines; SARS; influenza; pneumococcal infection; Streptococcus pneumoniae; Haemophilus influenzae; Hib; Respiratory Syncitial Virus; RSV; parainfluenza viruses; PIV; bronchiolitis;
D O I
10.1016/j.vaccine.2005.07.046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Worldwide, acute respiratory infections (ARls) constitute the leading cause of acute illnesses, being responsible for nearly 4 million deaths every year, mostly in young children and infants in developing countries. The main infectious agents responsible for ARIs include influenza virus, respiratory syncytial virus (RSV), parainfluenza virus type 3 (PIV-3), Streptococcus pneumoniae and Haemophilus influenzae. While effective vaccines against influenza, H. inflitenzae type b (Hib) and S. pneumoniae infections have been available for several years, no vaccine is available at present against illnesses caused by RSV, PIV-3, metapneurnovirus or any of the three novel coronaviruses. In addition, the threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines with broader spectrum of efficacy, which could provide immunity against an avian influenza virus pandemic. This article reviews the state of the art in vaccine R&D against ARIs and attempts to address these basic public health questions. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:5708 / 5724
页数:17
相关论文
共 107 条
  • [1] THE ETIOLOGY OF PNEUMONIA IN MALNOURISHED AND WELL-NOURISHED GAMBIAN CHILDREN
    ADEGBOLA, RA
    FALADE, AG
    SAM, BE
    AIDOO, M
    BALDEH, I
    HAZLETT, D
    WHITTLE, H
    GREENWOOD, BM
    MULHOLLAND, EK
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (11) : 975 - 982
  • [2] Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine
    Adegbola, RA
    Usen, SO
    Weber, M
    Lloyd-Evans, N
    Jobe, K
    Mulholland, K
    McAdam, KPWJ
    Greenwood, BM
    Milligan, PJM
    [J]. LANCET, 1999, 354 (9184) : 1091 - 1092
  • [3] Current status of live attenuated influenza virus vaccine in the US
    Belshe, RB
    [J]. VIRUS RESEARCH, 2004, 103 (1-2) : 177 - 185
  • [4] BELSHE RB, 2004, VACCINES, P371
  • [5] Inhibition of respiratory viruses by nasally administered siRNA
    Bitko, V
    Musiyenko, A
    Shulyayeva, O
    Barik, S
    [J]. NATURE MEDICINE, 2005, 11 (01) : 50 - 55
  • [6] BLACK S, 2004, 4 INT S PNEUM PNEUM
  • [7] Pneumococcal vaccines:: an update on current strategies
    Bogaert, D
    Hermans, PWM
    Adrian, PV
    Rümke, HC
    de Groot, R
    [J]. VACCINE, 2004, 22 (17-18) : 2209 - 2220
  • [8] The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex
    Bosch, BJ
    van der Zee, R
    de Haan, CAM
    Rottier, PJM
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (16) : 8801 - 8811
  • [9] Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine?
    Briles, DE
    [J]. MECHANISMS OF AGEING AND DEVELOPMENT, 2004, 125 (02) : 129 - 131
  • [10] Cassetti Maria Cristina, 2005, Vaccine, V23, P1529, DOI 10.1016/j.vaccine.2004.09.004